These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1652350)

  • 21. Immune globulin therapy in allogeneic bone marrow transplant: a critical review.
    Guglielmo BJ; Wong-Beringer A; Linker CA
    Bone Marrow Transplant; 1994 May; 13(5):499-510. PubMed ID: 8054903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
    Condie RM; O'Reilly RJ
    Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of severe cytomegalovirus infection with ganciclovir and high-dose intravenous immunoglobulin in patients with allogeneic bone marrow transplants. A pilot study.
    Lehn P; Quessar A; Devergie A; Esperou-Bourdeau H; Traineau R; Trédaniel J; Benbunan M; Bussel A; Jolivet I; Mazeron MC
    Nouv Rev Fr Hematol (1978); 1990; 32(1):17-20. PubMed ID: 2161510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus induces interstitial lung disease in allogeneic bone marrow transplant recipient rats independent of acute graft-versus-host response.
    Stals FS; Steinhoff G; Wagenaar SS; van Breda Vriesman JP; Haverich A; Dormans P; Moeller F; Bruggeman CA
    Lab Invest; 1996 Feb; 74(2):343-52. PubMed ID: 8780154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
    Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation].
    Winston DJ; Ho WG; Lin GH; Bartoni K; Budinger MD; Gale RP; Champlin RE
    Immun Infekt; 1985 Nov; 13(6):296-301. PubMed ID: 3000923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.
    Schwaighofer H; Oberhuber G; Hebart H; Einsele H; Herold M; Nachbaur D; Eibl B; Tilg H; Kropshofer G; Ferrara JL; Niederwieser D
    Transplantation; 1997 Jan; 63(1):52-6. PubMed ID: 9000660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin.
    Krischer J; Elfenbein G; Babington R; Hong R; Jansen J; Lazarus H; Winton E; Rand K
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):89-95. PubMed ID: 1324530
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early and late interstitial pneumonia following human bone marrow transplantation.
    Sullivan KM; Meyers JD; Flournoy N; Storb R; Thomas ED
    Int J Cell Cloning; 1986; 4 Suppl 1():107-21. PubMed ID: 3018098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation.
    Jacobsen N; Schäfer U; Ostendorf P; Kubaneck B; Wolf H
    Tokai J Exp Clin Med; 1985 Jun; 10(2-3):193-5. PubMed ID: 3010510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation.
    Tsinontides AC; Bechtel TP
    Ann Pharmacother; 1996 Nov; 30(11):1277-90. PubMed ID: 8913411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical and biological evaluation of the preventive role of anti-cytomegalovirus specific immunoglobulins in bone marrow grafts. Randomized study of 60 patients].
    Bordigoni P; Janot C; Aymard JP; Witz F; Bené MC; Legras B; Schoonemann F; Olive D; Streiff F
    Nouv Rev Fr Hematol (1978); 1987; 29(5):289-93. PubMed ID: 2830588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
    Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
    Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
    Funada H; Harada M; Yoshida T; Hattori K
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of early interstitial pneumonitis (IP) after BMT by exclusion of CMV-IG-POS platelet donors, prophylaxis with CMV immune globuline, and by a modified TBI regimen.
    Hinterberger W; Alth G; Höcker P; Kallinger W; Kier P; Kolbabek H; Lechner K; Popov-Kraup T
    Bone Marrow Transplant; 1991; 7 Suppl 2():43. PubMed ID: 1652329
    [No Abstract]   [Full Text] [Related]  

  • 38. Progress in the prevention of cytomegalovirus infection after allogeneic bone marrow transplantation.
    Devergie A; Traineau R; Esperou-Bourdeau H; Ribaud P; Socié G; Richard P; Selimi F; Hirsch I; Gluckman E
    Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S89-90. PubMed ID: 8177726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous immune globulin prophylaxis in recipients of a marrow transplant.
    Sullivan KM
    J Allergy Clin Immunol; 1989 Oct; 84(4 Pt 2):632-8; discussion 638-9. PubMed ID: 2551949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus immune plasma in bone marrow transplant recipients.
    Winston DJ; Pollard RB; Ho WG; Gallagher JG; Rasmussen LE; Huang SN; Lin CH; Gossett TG; Merigan TC; Gale RP
    Ann Intern Med; 1982 Jul; 97(1):11-8. PubMed ID: 6283982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.